[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.90.95. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 1996

Generalized Atrophic Benign Epidermolysis BullosaEither 180-kd Bullous Pemphigoid Antigen or Laminin-5 Deficiency

Author Affiliations

From the Departments of Dermatology, Groningen University Hospital, Groningen (Drs Jonkman and De Jong, and Mr Heeres), and University Hospital, Nijmegen (Dr Steijlen), and Department of Cell Biology, the Netherlands Cancer Institute, Amsterdam (Dr Sonnenberg), the Netherlands; School of Informatics and Sciences, Nagoya University, Nagoya, Japan (Dr Owaribe); Departments of Dermatology, University of Marburg, Marburg (Dr Küster), Ludwig-Maximilian-University, Munich (Dr Meurer), and University of Munster, Munster (Dr Bruckner-Tuderman), Germany; and Department of Dermatology and Institute of Forensic Medicine, National Hospital, Oslo, Norway (Dr Gedde-Dahl).

Arch Dermatol. 1996;132(2):145-150. doi:10.1001/archderm.1996.03890260047007
Abstract

Background:  Generalized atrophic benign epidermolysis bullosa (GABEB) is a form of nonlethal junctional epidermolysis bullosa, clinically characterized by generalized blistering after birth, atrophic healing, and incomplete universal atrophic alopecia with onset in childhood. Recently, we discovered a deficiency of the 180-kd bullous pemphigoid antigen (BP180) and a reduced amount of BP180 messenger RNA in three patients with GABEB. It is not yet clear, however, whether GABEB is invariably caused by BP180 deficiency.

Results:  We examined 18 patients with nonlethal junctional epidermolysis bullosa from unrelated families; nine of these individuals presented with the clinical characteristics of GABEB. Specimens of clinically normal skin obtained from the patients were stained by immunofluorescence with monoclonal antibodies to BP180 and laminin-5. The BP180 epitopes were not expressed in eight patients, all of whom were sharing the typical clinical features of GABEB. In one of the nine patients with GABEB, the BP180 level was sufficient, but the laminin-5 level was reduced. Among the nine patients with junctional epidermolysis bullosa without atrophic alopecia, laminin-5 level was not expressed in one patient, while in the other patients both antigens were normally expressed.

Conclusions:  Not all patients with GABEB are deficient in BP180, since some individuals with GABEB only exhibit reduction of the laminin-5 expression. The BP180 deficiency in the skin invariably seems to result in GABEB. Immunofluorescence analysis using monoclonal antibodies against BP180 (and laminin-5) may allow early subtyping, which is of prognostic significance, in children born with junctional epidermolysis bullosa.(Arch Dermatol. 1996;132:145-150)

×